European Association for the Study of Diabetes (EASD) congress 2022
What’s new from European Association for the Study of Diabetes 2022 Congress - Type 1 diabetes therapies, dietary guidelines, CV risk and expanding utility of GLP-1 RAs
Contents
2022 ADA/EASD consensus on type 2 diabetes treatment
Updated dietary guidelines
Diet and all-cause mortality
GLP-1 RA – from here to eternity
Dual GLP/GLP-1 RA – SURMOUNT obesity trial
SGLT-2 inhibitors:
DELIVER trial
Effect on epicardial adipose tissue
Type 1 diabetes – the future
Cardiovascular risk – what’s new?
Insulin therapy – simple, simpler, safest
Precision medicine and time-in-range
To access this module, please register or login: